In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
Introduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS)
2014-08-01
|
Series: | Clinical and Biomedical Research |
Subjects: | |
Online Access: | http://seer.ufrgs.br/index.php/hcpa/article/view/48369 |
id |
doaj-0fec0216a696406eb487881039d90de4 |
---|---|
record_format |
Article |
spelling |
doaj-0fec0216a696406eb487881039d90de42020-11-25T02:26:37ZengHospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS)Clinical and Biomedical Research0101-55752357-97302014-08-0134325371In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assayGustavo Enck Sambrano0Thiago Galvão da Silva Paim1Lucas Toniolo da Silva2Pedro Alves d'Azevedo3UFCSPAUFCSPAUFCSPAUFCSPAIntroduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to Enterococcus spp. However, several instances of emergence of resistance during linezolid treatment have been reported. The aim of this study was evaluate the activity of tigecycline against Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococcus faecalis (LRE) by the time-kill assay. Methods: Five isolates of LRE and two isolates of LIE were used in this study. MICs were determined by broth dilution following the CLSI (2014) guidelines. Time-kill assay was employed to access the in vitro response profile of tigecycline. Results: All seven of the isolates presented MIC of 0.125μg/mL. Tigecycline activity was individually evaluated and in three of the five isolates of LRE it presented bactericidal. Against the other isolates, tigecycline showed bacteriostatic activity. The tigecycline activity was measured according to CLSI criteria. Conclusions: Tigecycline presented both bacteriostatic and bactericidal activity against tested isolates, result not yet described in previous studies. Time and concentrations above MIC were key factors to achieving bactericidal effect. MIC and the tested concentration below it resulted in bacteriostatical effect to enterococci, corroborating previous data.http://seer.ufrgs.br/index.php/hcpa/article/view/48369EnterococcusAnti-Infective AgentsBacterial Growth |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gustavo Enck Sambrano Thiago Galvão da Silva Paim Lucas Toniolo da Silva Pedro Alves d'Azevedo |
spellingShingle |
Gustavo Enck Sambrano Thiago Galvão da Silva Paim Lucas Toniolo da Silva Pedro Alves d'Azevedo In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay Clinical and Biomedical Research Enterococcus Anti-Infective Agents Bacterial Growth |
author_facet |
Gustavo Enck Sambrano Thiago Galvão da Silva Paim Lucas Toniolo da Silva Pedro Alves d'Azevedo |
author_sort |
Gustavo Enck Sambrano |
title |
In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay |
title_short |
In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay |
title_full |
In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay |
title_fullStr |
In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay |
title_full_unstemmed |
In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay |
title_sort |
in vitro antibacterial activity of tigecycline against clinical isolates of linezolid-intermediate (lie) and linezolid-resistant enterococci (lre) by time-kill assay |
publisher |
Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS) |
series |
Clinical and Biomedical Research |
issn |
0101-5575 2357-9730 |
publishDate |
2014-08-01 |
description |
Introduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to Enterococcus spp. However, several instances of emergence of resistance during linezolid treatment have been reported. The aim of this study was evaluate the activity of tigecycline against Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococcus faecalis (LRE) by the time-kill assay.
Methods: Five isolates of LRE and two isolates of LIE were used in this study. MICs were determined by broth dilution following the CLSI (2014) guidelines. Time-kill assay was employed to access the in vitro response profile of tigecycline.
Results: All seven of the isolates presented MIC of 0.125μg/mL. Tigecycline activity was individually evaluated and in three of the five isolates of LRE it presented bactericidal. Against the other isolates, tigecycline showed bacteriostatic activity. The tigecycline activity was measured according to CLSI criteria.
Conclusions: Tigecycline presented both bacteriostatic and bactericidal activity against tested isolates, result not yet described in previous studies. Time and concentrations above MIC were key factors to achieving bactericidal effect. MIC and the tested concentration below it resulted in bacteriostatical effect to enterococci, corroborating previous data. |
topic |
Enterococcus Anti-Infective Agents Bacterial Growth |
url |
http://seer.ufrgs.br/index.php/hcpa/article/view/48369 |
work_keys_str_mv |
AT gustavoencksambrano invitroantibacterialactivityoftigecyclineagainstclinicalisolatesoflinezolidintermediatelieandlinezolidresistantenterococcilrebytimekillassay AT thiagogalvaodasilvapaim invitroantibacterialactivityoftigecyclineagainstclinicalisolatesoflinezolidintermediatelieandlinezolidresistantenterococcilrebytimekillassay AT lucastoniolodasilva invitroantibacterialactivityoftigecyclineagainstclinicalisolatesoflinezolidintermediatelieandlinezolidresistantenterococcilrebytimekillassay AT pedroalvesdazevedo invitroantibacterialactivityoftigecyclineagainstclinicalisolatesoflinezolidintermediatelieandlinezolidresistantenterococcilrebytimekillassay |
_version_ |
1724845863003488256 |